We evaluated the therapeutic efficacy and neurotoxicity of adenovirus-mediated transduction of the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) for experimental malignant brain tumors. The 5-FC sensitivity in 9 L cells infected by an adenovirus vector expressing CD (AdexCACD) was increased 1700-fold compared with control cells. Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC. The rats demonstrated remarkable inhibition of tumor growth by magnetic resonance imaging, and 7 of 10 rats survived for Ͼ90 days. To evaluate the potential side-effects of the 5-FC/CD gene therapy, rats were treated with an intracerebral injection of AdexCACD into the right basal ganglia and with 5-FC. The magnetic resonance imaging showed a highly enhanced area on the gadollinium-enhanced T1-weighted image at 18 days postinjection. Pathologically, this corresponded to an area of necrosis with surrounding apoptotic cells. In addition, there was demyelination and gliosis with enlargement of the lateral ventricles. These results suggest that the 5-FC/CD gene therapy may provide an anticancer effect for malignant brain tumors in humans, but also show that there are neurotoxic effects on normal brain tissue. Cancer Gene Therapy (2000) 7, 74 -82
D
espite recent advances in neurosurgical techniques, neuroradiological imaging modalities, radiation therapy, and chemotherapy, malignant gliomas still have a poor prognosis. Because tumor recurrences occur at the primary site in 90% of glioma patients, local control may improve patient survival rates. 1 Several gene therapies have been developed and, in some instances, tested in humans in an adjuvant setting. Among them, prodrugactivating gene therapy (suicide gene therapy) is one of the strategies employed for tumor reduction. These include ganciclovir (GCV)/herpes simplex virus thymidine kinase (HSV-TK), [2] [3] [4] [5] cyclophosphamide/cytochrome p450 2B1, 6 ,7 and 6-thioxanthine/Escherichia coli gpt. 8, 9 Transduction of the E. coli cytosine deaminase (CD) gene into tumor cells and administration of 5-fluorocytosine (5-FC) is also one of the suicide gene therapies for malignant tumors. 10 Expression of this gene within the target cell produces an enzyme that can convert the prodrug, 5-FC, to the toxic metabolite, 5-fluorouracil (5-FU). 5-FC may be particularly suitable for brain tumors, because it can readily cross the blood-brain barrier (BBB). 11 Anticancer effects of the CD/5-FC system have been observed for several solid tumors. [12] [13] [14] [15] [16] [17] 5-FC/CD gene therapy also possesses a strong bystander effect that does not require direct cell-to-cell contact. 17 Therefore, tumor regression can occur when treated with a nontoxic level of 5-FC, even if only a small percentage of cells expresses CD. 18, 19 5-FC/CD gene therapy has also been shown to enhance the effect of radiation in vitro and in vivo. 20, 21 There are particular factors to be considered when applying a therapy to the central nervous system, such as the BBB permeability of drugs, immune responses to vectors, and brain edema caused by gene therapy. Thus, we have investigated the feasibility of 5-FC/CD gene therapy for treating brain tumors. In a similar study, Dong et al 17 treated experimental gliomas using adenovirus. However, potential toxicities for the normal brain related to 5-FC/CD therapy were not examined in detail. Lan et al 14 observed significant hepatic toxicity using adenovirus-mediated delivery of CD in a gastric cancer model. Evaluation of toxic side-effects is an important factor in therapy, and we have analyzed the cytotoxic effect for neural tissues in 5-FC/CD gene therapy using sequential magnetic resonance imaging (MRI) and histological examination.
MATERIALS AND METHODS

Preparation of recombinant adenovirus vectors
Two recombinant replication-deficient adenovirus vectors, AdexCALacZ and AdexCACD, were constructed from a serotype 5 wild-type adenovirus (Ad5) by inserting the chicken alphaglobin promoter driving the E. coli lacZ gene or the E. coli CD gene into the E1 region of the genome. This adenovirus also possesses a deleted E3 region. The recombinant adenovirus vector AdexCACD was prepared according to a method described previously.
14,22 Viral stocks were produced by infecting 293 cells (transformed human embryonal kidney cells) (JCRB9068, Health Science Research Resources Bank, Osaka, Japan) with recombinant adenoviruses and were purified by CsCl density-gradient centrifugation, dialyzed against phosphate-buffered saline (PBS) containing 10% glycerol, and stored at Ϫ80°C. Viral titer was determined by endpoint cytopathic effect assay on 293 cells and expressed as plaqueforming units (PFU) per milliliter. 23 Purification of the AdexCALacZ and AdexCACD viruses yielded concentrations of 1.0 ϫ 10 10 PFU/mL and 2.6 ϫ 10 10 PFU/mL, respectively.
Cell lines
Rat 9 L gliosarcoma cells were grown in Eagle's minimum essential medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine sera (Life Technologies), 40 U/mL penicillin G, and 100 g/mL streptomycin. 293 cells were grown in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine sera, 40 U/mL penicillin G, and 100 g/mL streptomycin. The cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
CD enzyme activity assay
To show that AdexCACD vectors can produce a functional CD enzyme, we selectively measured the concentration of 5-FU converted from 5-FC in the culture medium of infected 9 L cells with AdexCACD vectors. A total of 1 ϫ 10 5 9 L cells were seeded in a 24-well plate and infected with AdexCACD at a multiplicity of infection (MOI) of 50. After 24 hours, medium containing 5-FC (50 g/mL) (Roche Japan, Tokyo, Japan) was added and incubated. After 1-6 days of incubation, supernatant was collected and its 5-FU concentration was measured by high performance liquid chromatography (HPLC). 24 
5-FC chemosensitivity of AdexCACD-infected 9 L cells
To show that transduction of the CD gene sensitizes cells to 5-FC, 9 L cells were seeded in a 96-well microtiter plate at a density of 2000 cells/well and infected with AdexCACD at an MOI of 0 -100 or with AdexCALacZ at an MOI of 100 as a control. At 24 hours after the initial incubation, medium containing 5-FC at various concentrations ranging from 0.1 to 1000 g/mL was added. After 6 days, the percentage of surviving cells was determined to evaluate drug chemosensitivity. The cells were incubated for 4 hours with the mitochondrial substrate 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, Mo), which can be transformed in formazan only by living cells. After cell lysis in the presence of 0.04 M 2-propanolic hydrochloric acid, the optical density of each well was measured at 540 nm using a microplate spectrophotometer.
Analysis of the in vitro bystander effect
To determine whether AdexCACD mediated the production of sufficient amounts of 5-FU to affect neighboring cells (i.e., a bystander effect), 1 ϫ 10 4 9 L cells were seeded in 75-cm 2 dishes and infected with AdexCACD at an MOI of 25 or were mock-infected. After 24 hours, cells were resuspended in fresh medium and mixed in varying percentages of infected and uninfected cells (0 -100%). Cells were seeded in a 24-well plate at a density of 2000 cells/well. At 24 hours after the initial incubation, medium containing 5-FC (0 or 50 g/mL) was added. This cell mixture was maintained in culture for 6 days, and the percentage of surviving cells was then determined using the MTT assay.
In vivo transgene expression
Experimental animals were housed and handled in accordance with Okayama University Animal Research Committee guidelines. Male Wistar rats (Charles River Laboratories, Osaka, Japan) weighing 250 -300 g each were used for animal experiments. To establish the brain tumor model, rats were anesthetized with intraperitoneal (i.p.) nembutal (30 mg/kg) and placed in a stereotactic apparatus (Narishige, Tokyo, Japan). 9 L cells (1 ϫ 10 4 cells/5 L) were slowly injected into the basal ganglia of the right cerebral hemisphere (4 mm lateral to the midline, 2 mm posterior to the coronal suture, 5 mm deep from the dura) using a Hamilton syringe (Hamilton, Reno, Nev), according to previously published procedures. 9, 25 To evaluate transgene expression and distribution in the tumor and the surrounding normal brain, rats bearing 4-day-old brain tumors were reanesthetized and received an intratumoral (i.t.) injection of AdexCALacZ (1 ϫ 10 8 PFU/10 L) using the same stereotactic coordinates. Animals were sacrificed 4 -14 days after vector injections and fixed in vivo by transcardiac perfusion with 4% formaldehyde. Their brains were then frozen and sliced into 40-m sections, and LacZ expression was detected by 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) staining.
In vivo antitumor activity of 5-FC/CD gene therapy . Treatment with i.p. 5-FC (500 mg/kg) or PBS (for control) was started 48 hours after vector injection and repeated once a day for 2 weeks. Animals were observed and sacrificed near death. Tumor masses were monitored using T1-weighted and T2-weighted images of MRI. Animals were anesthetized with nembutal (30 mg/kg) and were placed in a Quadratur transmit/receive head coil that was 28 cm in diameter. After an intravenous injection of gadollinium-diethyenetriaminepenta-acetic acid (Gd-DTPA) (1.0 mL/kg), coronal T1-weighted images (TR 500 msec, TE 20 msec, 3-mm thickness, gapless) were obtained with a 1.5-tesla superconducting magnet magnetic resonance device (Signa Advantage version 5.4, General Electronic, Milwaukee, Wis). MRI studies were started 18 days after tumor inoculation and continued at selected intervals thereafter.
Toxicity study
The toxicity of 5-FC/CD gene therapy was evaluated. To evaluate transgene expression, 12 rats were treated with an intracerebral injection of the AdexCALacZ vector (1 ϫ 10 8 PFU/10 L) into the right basal ganglia. Animals were sacrificed starting at the 4-day timepoint and continuing for Յ3 months after vector injection. Brain sections were then stained with X-Gal. To evaluate the potential side-effects of adenovirus-mediated transduction of the CD gene and systemic administration of 5-FC on normal brain tissues, another 12 rats were treated with intracerebral injections of AdexCACD (1 ϫ
10
8 PFU/10 L) into the right basal ganglia. A total of 6 of 12 rats were treated with i.p. 5-FC (500 mg/kg) once a day for 2 weeks. At different intervals, rat brains were visually monitored using MRI and were harvested for pathological studies. T1-and T2-weighted images of MRI were also performed to detect inflammation, necrosis, and edema. Histological techniques such as hematoxylin-eosin (HE) and Kluver-Barrera (KB) staining were employed to detect demyelination of white matter. Immunostaining for the detection of apoptotic cells was performed using a commercially available kit (ApopTag ϩ , Oncor, Gaithersburg, Md).
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RESULTS
CD enzyme activity
The concentration of 5-FU increased in a time-dependent fashion in the supernatant of 9 L cells infected with the AdexCACD vector (Fig 1) . The conversion of 5-FC to 5-FU was measured using HPLC. The mean conversion ratio was 86% (Ϯ 4.5, SE) after 6 days of incubation. This result indicated that 5-FC was efficiently converted by AdexCACD-infected cells and that 5-FU was freely diffusible across cell membranes.
Chemosensitivity of AdexCACD-infected 9 L cells to 5-FC Cell viability was not affected when 9 L cells were infected with AdexCALacZ at an MOI of 1000 or infected with AdexCACD at an MOI of 100 without 5-FC treatment. The sensitivity of AdexCACD-infected 9 L cells to 5-FC increased in an MOI-dependent and 5-FC dose-dependent manner (Fig 2) . The 5-FC concentration that inhibited cell growth by 50% was 320 g/mL in control 9 L cells and 2.4 g/mL (a 130-fold reduction) and 0.19 g/mL (a 1700-fold reduction) in 9 L cells infected with AdexCACD at MOIs of 10 and 100, respectively. High concentrations of 5-FC (Ͼ50 g/mL) were toxic to uninfected 9 L cells or AdexCALacZinfected 9 L cells.
In vitro bystander effect Different mixtures of 9 L cells and AdexCACD-infected 9 L cells were plated in tissue culture dishes. A total of 50 g/mL of 5-FC was added to the cell populations 24 hours after plating, and the percentage of living cells was determined using the MTT assay. Growth suppression was observed when only 1% of cells had been infected with AdexCACD vector followed by 5-FC. Growth suppression equal to that observed with 100% infected cells could be obtained when 10% of cells had been infected (Fig 3) . In our MTT assay, Ͻ20% of control indicated that almost all tumor cells were killed with the microscopic inspection.
In vivo transgene expression A stereotactic injection of AdexCALacZ vector (1 ϫ 10 8 PFU/10 L) into brain tumors resulted in significant staining of tumor cells at 4 days after vector injection, and the transduction rate at the periphery of the tumor was higher than that at the core of the tumor. (Fig 4A) . The transduction rate of the tumor continued at the same level for 7 days after vector injection and then gradually decreased by the day 14 timepoint. At the tumor margin, there was positive staining for X-Gal not only in tumor cells but also in normal cells (Fig 4B) compared with specimens stained with HE. Positive normal cells were observed only at the border between tumor and normal tissue, and not in areas distant from the tumor mass.
In vivo antitumor effect
Tumor size could not be accurately evaluated on Gdenhanced, T1-weighted images of MRI until the 18 day timepoint after tumor inoculation. Rats in the five control groups (vehicle ϩ PBS, vehicle ϩ 5-FC, AdexCALacZ ϩ PBS, AdexCALacZ ϩ 5-FC, and Adex-CACD ϩ PBS) rapidly developed brain tumors with remarkable enhancement (Fig 5A) . No difference in tumor size was observed among the five control groups. When compared with these control tumors, there were very small areas of enhancement in rats treated with AdexCACD and 5-FC; these areas were apparent at 18 days after tumor inoculation (Fig 5B) . The size of the enhanced areas was Ͻ2.2 mm in diameter in treated animals. Some showed homogeneous enhancement, whereas others exhibited ring-like enhancement containing central necrosis. At 60 days after tumor inoculation, we detected a gradual decrease of the enhanced area as well as a hypointense area around the injection site in 7 of 10 rats; these rats were still surviving by 90 days (Fig 5C) . To evaluate the in vivo antitumor effect, the long-term survival of the rats bearing 9 L brain tumors was analyzed (Fig 6) . Toxicity of systemic administration of 5-FC was not observed when rats were treated with an i.p. injection of 1000 mg/kg/day 5-FC for 14 days without intracerebral injection of adenovirus vectors (data not shown). Rats in the five control groups (vehicle ϩ PBS, vehicle ϩ 5-FC, AdexCALacZ ϩ PBS, AdexCALacZ ϩ 5-FC, and AdexCACD ϩ PBS) died due to tumor with respective median survival times of 27, 27, 26, 26, and 23 days. A total of 7 of 10 rats treated with AdexCACD (1 ϫ 10 8 PFU/10 L) and 5-FC survived for Ͼ90 days. Use of higher doses of Adex-CACD (2 ϫ 10 8 PFU/10 L) and 5-FC resulted in an increase in survival, with 9 of 10 rats surviving for Ͼ90 days. During the 5-FC treatment period, a minimum amount of weight loss was observed. Rats were sacrificed near death or at 90 days after tumor inoculation, and brains were harvested for pathological study. Surviving rats treated with AdexCACD and 5-FC showed no evidence of tumors around the inoculation site. They had a small area of necrosis at the site of inoculation (Fig 4C) . Further, mild atrophy of the basal ganglia and dilatation of the lateral ventricle were present in some of the surviving rats.
Toxicity of AdexCACD and 5-FC on the normal rat brain
A stereotactic injection of AdexCALacZ vectors (1 ϫ 10 8 PFU/10 L) into the basal ganglia of the normal brain provided evidence for distribution of adenovirus. The extent of the transduced area was greater than seen for an i.t. injection with the same dose of vector (Fig 4,  A and D) . Although X-Gal-positive cells were seen mainly in basal ganglia around the injection site, faint and patchy areas of expression were recognized in the ipsilateral hemisphere and corpus callosum in some rats. Microscopic findings showed that positive cells were independent of cell type, in that astrocytes, ependymal Note that the X-Gal-positive cells are not only in the tumor but also in the normal brain (ϫ200 magnification). C: Histopathology of the brain from the rat that had received 9 L tumor inoculation and was subsequently treated with i.t. AdexCACD and systemic 5-FC. The rat was perfused (sacrificed) at 90 days after tumor inoculation. The 9 L tumor disappeared, and necrotic cavity was present around the injection site. There was a thin layer of gliosis at the border of the normal brain and necrotic cavity (HE staining, ϫ400 magnification). D: A stereotactic injection of AdexCALacZ into normal basal ganglia resulted in diffuse staining of all cell types, such as astrocytes, ependymal cells, and neurons, around the injection site at 7 days after vector injection. Note that the greater area is transduced compared with i.t. vector injection at the same amount of PFU. E,F: The brain section from the normal rat that had received AdexCACD into the basal ganglia (E) and was also treated with i.p. 5-FC (F) (HE staining). A larger damaged area around the injection site and partial hydrocephalus can be seen in (F). G: Immunostaining for the detection of apoptotic cells. The rat treated with AdexCACD plus i.p. 5-FC was analyzed at day 18. Apoptotic cells were scattered in the edematous brain around the injection site, showing evidence of cytotoxicity (ϫ400 magnification). H: KB staining for the detection of demyelination. The effect of AdexCACD plus i.p. 5-FC was observed around the basal ganglia. cells, and neurons exhibited equivalent staining. Little cytotoxic effects with minimal necrosis at the center of the injection site were observed on HE staining. No clinical or neurological toxicity was seen in animals. To evaluate the potential side-effects of both AdexCACD adenovirus vectors and 5-FC/CD gene therapy on normal brain tissue, six rats received an intracerebral injection of AdexCACD vectors, whereas another six rats received an intracerebral injection of AdexCACD vectors followed by i.p. 5-FC (500 mg/kg) for 2 weeks. Rats were sacrificed at different time intervals, and brains were harvested for pathological studies. The brains of rats treated with AdexCALacZ alone (Fig 4D) or with AdexCACD alone (Fig 4E) exhibited a small area of necrosis at the site of injection from 14 to 60 days. Although a small area of necrosis with limited gliosis was observed at the site of injection, there was no histological evidence of toxicity in the adjacent brain parenchyma. There was no significant difference in the size of necrosis between rats treated with AdexCACD and AdexCALacZ. However, intracerebral AdexCACD vector injection followed by systemic 5-FC produced cytotoxicity in normal brains. Immediately after treatment, brain sections from the AdexCACD ϩ 5-FC treatment groups had larger necrotic areas compared with other control groups around the injection sites. Further, hydrocephalus was present in two of six rats, whereas this pathological change was never seen in control groups (Fig 4F) . Microscopic examination showed necrosis with bleeding and macrophages surrounded by a ring of polymorphonuclear and lymphocytic cells. In adjacent white matter, there was spongiosis, indicating inflammation and edema, and focal collections of polymorphonuclear and lymphocytic cells. These findings were compatible with the MRI findings described in subsequent paragraphs. Apoptotic cells detected by immunostaining were scattered in the same areas as surrounding edematous lesions, showing evidence of cytotoxicity (Fig 4G) . At later stages, necrotic areas became larger and chronic brain reactions were observed. Typical gliotic changes after inflammation were observed around the cavity of necrosis. KB staining clearly showed demyelination in the white matter around the basal ganglia, and in some cases within the corpus callosum (Fig 4H) . At 18 days after AdexCACD vector injection with i.p. 5-FC, highly enhanced areas were demonstrated in the basal ganglia around the injection site of vectors on Gd-enhanced T1 sequences of MRI (Fig 5D) . T2 sequences showed high-intensity areas corresponding to brain edema and inflammation. The high-intensity areas on the T2 sequences were greater than those for the T1 sequences. In a few animals, edema was pronounced and present in the basal ganglia and corpus callosum. At 60 days posttreatment, we could not detect enhancing lesions on Gd-enhanced, T1-weighted images, but detected hypointense lesions, corresponding to necrosis, and brain edema as revealed by the hyperintensity seen on T2-weighted images.
DISCUSSION
Delivery of transgene in rat brain tumors using adenovirus vector To achieve successful anticancer effects against brain tumors, adequate delivery and expression of CD is essential. It is also important that toxicity to the normal brain should be minimal.
In the present study, efficient transduction of 9 L cells was observed by recombinant adenovirus vector injected into rat brain tumors. Because gene transduction by adenovirus vectors is independent of the host cell cycle, a high level of transduction of tumor cells was achieved. 5 Transduction by i.t. injection was relatively restricted to the tumor and did not reach the normal brain area far from the tumor. In addition, transduction rates were high at the periphery of the tumor. Viola et al 27 reported similar findings, and several causes can be considered: (a) accessibility of adenovirus vectors to border areas between the tumor and normal brain, (b) actively proliferating tumor rim, (c) peripheral tumor cells expressing receptors to adenovirus at a higher level than normal cells, 27, 28 and (d) technical problem of the i.t. injection. LacZ expression in the tumor maintained a high level for 7 days but subsequently decreased. Loss of transgene expression is multifactorial and is due to dilution by tumor cell division and selective destruction of infected cells by the host immune response. 29 -32 Antitumor effect of 5-FC/CD gene therapy 5-FU is a widely used chemotherapeutic agent. In addition, it has an antitumor effect on brain tumor cells. However, most clinical studies with 5-FU alone have indicated no value in the treatment of patients with malignant gliomas. 33 The primary limitation of systemic chemotherapy is due to a low therapeutic index. To overcome this problem, in vivo suicide gene therapy has the theoretical advantage of delivering high local concentrations of a therapeutic agent while minimizing systemic side-effects, resulting in increases in the therapeutic window.
The first trial of experimental therapy for malignancy using 5-FC/CD therapy was described by Nishiyama et al. 33 They implanted a CD capsule into the tumor bed that can convert systemically administered nontoxic 5-FC to highly toxic 5-FU to obtain a high local concentration of 5-FU and to minimize systemic toxicity. To achieve high and stable enzyme activity in tumor cells, Mullen 10 applied gene transfer methodologies to this system. Recently, 5-FC/CD gene therapy was used against solid tumors including colorectal, 12, 13 gastric, 14 hepatocellular, 15 breast cancers, 16 and glioma. 17, 34 Its antitumor effect is also enhanced by combination with radiotherapy. 20, 21 The advantages of 5-FC/CD gene therapy have been described. First, the mechanism of the antitumor effect is independent of the cell cycle. Second, the prodrug 5-FC is highly permeable and readily crosses the BBB. Cerebrospinal fluid distribution from the blood sera of 5-FC is ϳ60 -80%. 35 Drug delivery to the tumor is one of the most important factors for successful chemotherapy and can be the largest factor limiting clinical applications. Third, the bystander effect of 5-FC/CD gene therapy is strong and does not require direct cell-to-cell contact. As shown in our in vitro assay, 5-FU was present in the culture medium of infected 9 L cells with CD vectors, implying that the antitumor effect can act through the extracellular space or cerebrospinal fluid. Acquisition of CD increased the 5-FC sensitivity of 9 L cells by 1700-fold. In glioma cell lines such as C6 34 5-FC sensitivity was increased by ϳ2000-fold. We showed growth suppression when only 1% of cells had been infected with AdexCACD. Maximum growth suppression equal to that of 100% infected cells was seen when only 10% of cells had been infected in this study. Huber et al 18 have also reported that when only 2% of a colorectal tumor mass contains CD-expressing cells, significant regression in all tumors is observed when mice are treated with nontoxic levels of 5-FC. Similar results were reported by Trinh et al. 19 In contrast to 5-FC/CD gene therapy, the bystander effect of the HSV-TK/GCV system depends upon the formation of gap junctions between contact cells and upon the expression of connexin-43 in cells. 36 Namba et al 37 reported that a population of Ͼ25% of TK-positive cells was required for the complete elimination of experimental brain tumors.
Our in vivo results suggested that the combination of 5-FC/CD gene therapy mediated by adenovirus vectors had a tumoricidal effect in the rat tumor model. 5-FC/ CD-treated rats survived significantly longer than control groups. This finding was confirmed at two doses of adenovirus (1 ϫ 10 8 PFU/10 L and 2 ϫ 10 8 PFU/10 L). MRI was used as another method to evaluate therapeutic effects and was useful for the sequential observation of tumor size, edema, or necrotic cavity. 28, 37, 38 At 60 days posttreatment, surviving mice did not have a Gd-enhanced area, but showed evidence of necrosis on T1-weighted images.
Toxicity of the 5-FC/CD gene therapy For clinical trials, the side-effects of this system should be studied to determine prodrug and active drug toxicities. We analyzed the toxicity of adenovirus using MRI and histological techniques. Adenovirus injection without 5-FC treatment did not cause neurological deficits and did not show severe brain damage on MRI or on histology. However, at the tumor margin, X-Gal positivity was present not only in tumor cells but also in normal cells. Injection of adenovirus into the normal brain resulted in a broad and diffuse transduction of normal cells. Even if adenovirus infection to normal cells did not cause severe brain damage, the possibility of brain edema, encephalitis, or infarction was present. For clinical purposes, more selectivity for tumor cells should be acquired for safer gene therapy. Improvements of adenovirus have already been examined, such as "adenobody" 39 and specific promoters. 40 The prodrug used in this therapy, 5-FC, is clinically used as an antifungal agent. The dose of i.p. 5-FC for gene therapy ranges from 500 to 800 mg/kg/day. 14, 17, 20, 34 Considerable toxic effects on the normal brain by adenovirus-mediated transfer of the CD gene and i.p. 5-FC were also demonstrated by MRI and pathological studies, as shown in our results. Neuronal damage was demonstrated by brain edema, hydrocephalus, meningitis, large necrotic areas, and demyelination. Goodman et al 38 reported the toxicity of adenovirus-mediated HSV-TK/GCV gene therapy on infection into the brain of a baboon. In their report, injection of high doses (1.5 ϫ 10 9 PFU) of adenovirus caused animal death a few days later from GCV treatment. They observed coagulative necrosis, edema, and perivascular lymphocytosis with intensive treatment. Smith et al 41 also mentioned local toxicity of the same system in rat brains. Compared with animals that were treated with an injection of Adex-CACD into the normal basal ganglia and treated with 5-FC, animals that were treated with an i.t. injection of AdexCACD and 5-FC had mild toxicity in the normal brain. This was due to our results indicating that the adenovirus intended to infect tumor cells upon i.t. injection and that the gene transduction of i.t. injection was relatively restricted to the tumor and did not reach the normal brain area far from the tumor. Therefore, for clinical use of 5-FC/CD gene therapy mediated by adenovirus, it seems to be very important to inject the adenovirus vectors harboring the gene into the tumor mass. In the future, specific adenovirus vectors infecting only tumor cells should be developed for the success of this gene therapy.
Our results suggest that 5-FC/CD gene therapy may be a feasible treatment modality for malignant brain tumors in humans, although the lack of selectivity of adenovirus vector for tumor cells and the neuronal damage caused by converted 5-FC metabolites may limit its applications in humans.
